Immunome (IMNM) Total Non-Current Liabilities (2020 - 2023)
Immunome (IMNM) posted Total Non-Current Liabilities of $27.3 million for Q4 2023, down 68.59% on a QoQ basis from $87.0 million in Q3 2023, and up 272.64% year-over-year from $7.3 million in Q4 2022.
Immunome (IMNM) Total Non-Current Liabilities (2020 - 2023) Analysis & Trends
Immunome's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $27.3 million for Q4 2023.
- Quarterly Total Non-Current Liabilities rose 272.64% year-over-year to $27.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $27.3 million (up 272.64% YoY) and the FY2023 annual result came in at $27.3 million, up 272.64% from the prior year.
- Total Non-Current Liabilities was $27.3 million for Q4 2023 at Immunome, down from $87.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $87.0 million in Q3 2023 and bottomed at $5.6 million in Q3 2020.
- A 4-year average of $20.3 million and a median of $9.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 24.64% — and 2023, when it jumped 1080.12%.
- Immunome's Total Non-Current Liabilities stood at $5.6 million in 2020, then surged by 72.85% to $9.7 million in 2021, then retreated by 24.64% to $7.3 million in 2022, then soared by 272.64% to $27.3 million in 2023.
- Business Quant data shows IMNM's Total Non-Current Liabilities at $27.3 million in Q4 2023, $87.0 million in Q3 2023, and $7.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 27.32 Mn |
| Sep 30, 2023 | 86.96 Mn |
| Dec 31, 2022 | 7.33 Mn |
| Sep 30, 2022 | 7.37 Mn |
| Jun 30, 2022 | 8.62 Mn |
| Mar 31, 2022 | 9.71 Mn |
| Dec 31, 2021 | 9.73 Mn |
| Sep 30, 2020 | 5.63 Mn |